BioVie reports Phase 2 Long COVID drug trial results in subgroups
Tweet Send to a Friend
BioVie Inc. (NASDAQ: BIVI) released topline results from its Phase 2 ADDRESS-LC trial evaluating bezisterim, an investigational oral drug, for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
